Is Gyre Therapeutics, Inc. (GYRE) a Buy, Sell, or Hold?
NASDAQ : GYRE
Gyre Therapeutics, Inc.
$6.72 USD
$0.05 (0.75%)
- Volume
- 51.54K
- Average Volume
- 82.66K
- Market Capitalization
- $614.15M
- P/E Ratio
- -33.79
- Dividend Yield
- 0.00%
- Price Target
- $17.00
- Year High
- $9.42
- Year Low
- $5.44
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.26
Company Overview
NASDAQ
Ying Luo
Biotechnology
Healthcare
GYRE
625
US
USD
Liquidity Metrics
0.03
4.26
3.86
1.51
0.00
Sales & Valuation
$116.59M
5.14
5.19
142.10
0.04
Profitability
$0.0225
$5.03M
-14.52%
-13.49%
-15.77%
-8.70%
P/E Metrics
-33.79
-2.99
-2.99
Analyst Price Target & Rating
$17.00
$18.00
$16.00
2/5
1 Analysts
-60.47%
Financial Health Scores
10.58
1/9
$93.41M
$199.26M
$34.34M
-$16.04M
Key Metrics (TTM)
$569.71M
4.77
-40.63
4.26
-16.73%
-9.40%
-2.74%
0.71%
633 days
Company Executives
| Name | Title |
|---|---|
| Yue Xiong | Chief Scientific Officer & Director |
| Ying Luo | CEO, President & Director |
| Jing Liu | Senior Vice President of Platform Chemistry |
| Mark Marino | Senior Vice President of Clinical Development |
| Jialiang Wang | Executive VP & GM |
| Joshua Bergmann | General Counsel & Corporate Secretary |
| Thomas W. Eastling | Chief Financial Officer |
| Weiguo Ye | Chief Operating Officer |
| Ruoyu Chen | Chief Information Officer |
| Seth Goldblum | Senior Vice President of Corporate Development |
Poll Results
No votes yet today — be the first to share your view!
About Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated ... with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates
2026-08-07 09:20:50
Gyre Therapeutics, Inc. (GYRE) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.02 per share a year ago.
2026-08-07 07:00:00
Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China's CDE in May 2026 SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced financial results for the second quarter ended June 30, 2026, and provided a business update. Dr. Ying Luo, President and Chief Executive Officer of Gyre Therapeutics, commented, “I am very pleased with Gyre's progress over this last quarter, the highlights of which include the acquisition of Cullgen with its robust degrader pipeline and strong executive team, the NMPA acceptance of an NDA for F351 for CHB liver fibrosis, Gyre's second major product candidate after ETUARY™, and increased sales from our Gyre Pharmaceuticals division, which demonstrates our commercialization capabilities.
Gyre Therapeutics Appoints Three New Members to its Board of Directors
2026-07-16 16:05:00
SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced that its Board of Directors has appointed three new members, effective August 1, 2026: Yue Xiong, Ph.D., the Company's Chief Scientific Officer; Maxwell (“Max”) Kirkby; and Claire Weston, Ph.D. With these appointments, the Board expands its scientific, clinical development, and cross-border biopharmaceutical operating expertise as Gyre advances its broad pipeline of products targeting numerous therapeutic areas including fibrosis, cancer, inflammation and pain.
2026-05-27 20:01:00
Newtown Square, Pennsylvania--(Newsfile Corp. - May 27, 2026) - Kaskela Law LLC is investigating Gyre Therapeutics, Inc. (NASDAQ: GYRE) ("Gyre") on behalf of the company's long-term shareholders. The investigation seeks to determine whether Gyre and/or the company's officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.
New Strong Sell Stocks for May 27th
2026-05-27 09:21:12
GYRE, FSUN and AKZOY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2026.
2026-05-12 16:05:00
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for F351 (hydronidone) as a treatment for chronic hepatitis B (CHB)-induced liver fibrosis, which is liver damage resulting from the infection of the hepatitis B virus (HBV). The acceptance comes after the NMPA previously granted priority review status for F351 in March after Gyre submitted the NDA through its majority-owned subsidiary Gyre Pharmaceuticals Co., Ltd.
Frequently Asked Questions
-
What is the current Gyre Therapeutics, Inc. (GYRE) stock price?
-
Gyre Therapeutics, Inc.(NASDAQ:GYRE) stock price is $6.72 in the last trading session. During the trading session, GYRE stock reached the peak price of $9.42 while $5.44 was the lowest point it dropped to. The percentage change in GYRE stock occurred in the recent session was 0.75% while the dollar amount for the price change in GYRE stock was $0.05.
-
GYRE's industry and sector of operation?
-
The NASDAQ listed GYRE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GYRE?
-
Yue Xiong | Chief Scientific Officer & Director
Ying Luo | CEO, President & Director
Jing Liu | Senior Vice President of Platform Chemistry
Mark Marino | Senior Vice President of Clinical Development
Jialiang Wang | Executive VP & GM -
How many employees does GYRE have?
-
Number of GYRE employees currently stands at 625. GYRE operates from 12770 High Bluff Drive, San Diego, CA 92130, US.
-
Link for GYRE official website?
-
Official Website of GYRE is: https://www.gyretx.com
-
How do I contact GYRE?
-
GYRE could be contacted at phone #619 949 3681 and can also be accessed through its website. GYRE operates from 12770 High Bluff Drive, San Diego, CA 92130, US.
-
How many shares of GYRE are traded daily?
-
The average number of GYRE shares traded daily for last 3 months was 82.66K.
-
What is the market cap of GYRE currently?
-
The market value of GYRE currently stands at $614.15M with its latest stock price at $6.72